This Technical Assistance Publication (TAP), updated in 2021, provides guidance for behavioral health service and substance use disorder treatment programs wanting to develop or update a comprehensive, scalable, and flexible disaster plan. It addresses planning needs specific to programs that offer prevention services, outpatient or residential treatment, medically supervised withdrawal, and pharmacotherapy.

This tip sheet explores stress and compassion fatigue, as well as signs of distress after a disaster. It identifies ways to cope and enhance resilience, along with resources for more information and support.

Esta hoja informativa se puede usar como una guía para las personas que buscan tratamiento de salud mental. Ofrece tres pasos necesarios para llevar a cabo antes de utilizar un centro de tratamiento, así como las cinco señales de un centro de tratamiento de calidad, que incluye revisar la acreditación, la medicación, las prácticas basadas en la evidencia, el papel de las familias y las redes de apoyo.

This fact sheet serves as a guide for individuals seeking behavioral health treatment. It provides three necessary steps to complete prior to utilizing a treatment center and the five signs of a quality treatment center, which include a review of the accreditation, medication, evidence-based practices, position on the role of families, and support networks.

This fact sheet provides Health Care Practitioners and Disaster Responders with guidelines for communicating with survivors experiencing grief. It give background information about the grieving process and what happens when the grief process is interrupted and complicated or traumatic grief occurs is included as well as helpful resources for additional assistance.

This report offers best practices for implementing the Mental Health Parity and Addiction Equity Act of 2008. It covers processes for implementing parity and collaborating with other organizations. The report also discusses tools for understanding and monitoring compliance.

This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.

This report presents spending information for treatment of mental illness, substance use disorders, or both for people only enrolled in Medicaid, and those enrolled in both Medicaid and Medicare. The report also covers fee-for-service spending and managed care spending.